Study S001713

A Multicenter, Randomized, Open, Parallel-controlled, Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07046273
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 496
Start: 2025-08-01
Primary completion: 2028-08-01
Lead sponsor: Shandong New Time Pharmaceutical Co., LTD
Conditions: Type 2 Diabetes (T2DM)
Interventions: DRUG:F027; DRUG:Ozempic®
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change in HbA1c from baseline [Week 32]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.